These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 16026937

  • 21. Chronic fatigue syndrome: characteristics and possible causes for its pathogenesis.
    Bassi N, Amital D, Amital H, Doria A, Shoenfeld Y.
    Isr Med Assoc J; 2008 Jan; 10(1):79-82. PubMed ID: 18300582
    [Abstract] [Full Text] [Related]

  • 22. Regulation of feeding behavior by pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal polypeptide (VIP) in vertebrates.
    Matsuda K, Maruyama K.
    Peptides; 2007 Sep; 28(9):1761-6. PubMed ID: 17466413
    [Abstract] [Full Text] [Related]

  • 23. Pituitary adenylate cyclase-activating polypeptide induces translocation of its G-protein-coupled receptor into caveolin-enriched membrane microdomains, leading to enhanced cyclic AMP generation and neurite outgrowth in PC12 cells.
    Zhang W, Duan W, Cheung NS, Huang Z, Shao K, Li QT.
    J Neurochem; 2007 Nov; 103(3):1157-67. PubMed ID: 17680996
    [Abstract] [Full Text] [Related]

  • 24. Characterization and expression of different pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptors in rat ovarian follicles.
    Vaccari S, Latini S, Barberi M, Teti A, Stefanini M, Canipari R.
    J Endocrinol; 2006 Oct; 191(1):287-99. PubMed ID: 17065411
    [Abstract] [Full Text] [Related]

  • 25. Noncompensation in peptide/receptor gene expression and distinct behavioral phenotypes in VIP- and PACAP-deficient mice.
    Girard BA, Lelievre V, Braas KM, Razinia T, Vizzard MA, Ioffe Y, El Meskini R, Ronnett GV, Waschek JA, May V.
    J Neurochem; 2006 Oct; 99(2):499-513. PubMed ID: 17029602
    [Abstract] [Full Text] [Related]

  • 26. Characterization of novel splice variants of the PAC1 receptor in human neuroblastoma cells: consequences for signaling by VIP and PACAP.
    Lutz EM, Ronaldson E, Shaw P, Johnson MS, Holland PJ, Mitchell R.
    Mol Cell Neurosci; 2006 Feb; 31(2):193-209. PubMed ID: 16226889
    [Abstract] [Full Text] [Related]

  • 27. Role of VIP and PACAP in islet function.
    Winzell MS, Ahrén B.
    Peptides; 2007 Sep; 28(9):1805-13. PubMed ID: 17559974
    [Abstract] [Full Text] [Related]

  • 28. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
    Niller HH, Wolf H, Minarovits J.
    Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
    [Abstract] [Full Text] [Related]

  • 29. Bone morphogenetic protein down-regulation of neuronal pituitary adenylate cyclase-activating polypeptide and reciprocal effects on vasoactive intestinal peptide expression.
    Pavelock KA, Girard BM, Schutz KC, Braas KM, May V.
    J Neurochem; 2007 Feb; 100(3):603-16. PubMed ID: 17181550
    [Abstract] [Full Text] [Related]

  • 30. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
    Barberi M, Muciaccia B, Morelli MB, Stefanini M, Cecconi S, Canipari R.
    Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
    [Abstract] [Full Text] [Related]

  • 31. The neuropeptide pituitary adenylate cyclase activating polypeptide modulates Ca2+ and pro-inflammatory functions in human monocytes through the G protein-coupled receptors VPAC-1 and formyl peptide receptor-like 1.
    El Zein N, Badran B, Sariban E.
    Cell Calcium; 2008 Mar; 43(3):270-84. PubMed ID: 17651798
    [Abstract] [Full Text] [Related]

  • 32. Novel concepts of neuropeptide-based drug therapy: vasoactive intestinal polypeptide and its receptors.
    Groneberg DA, Rabe KF, Fischer A.
    Eur J Pharmacol; 2006 Mar 08; 533(1-3):182-94. PubMed ID: 16473346
    [Abstract] [Full Text] [Related]

  • 33. cAMP activation by PACAP/VIP stimulates IL-6 release and inhibits osteoblastic differentiation through VPAC2 receptor in osteoblastic MC3T3 cells.
    Nagata A, Tanaka T, Minezawa A, Poyurovsky M, Mayama T, Suzuki S, Hashimoto N, Yoshida T, Suyama K, Miyata A, Hosokawa H, Nakayama T, Tatsuno I.
    J Cell Physiol; 2009 Oct 08; 221(1):75-83. PubMed ID: 19496170
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. PACAP, VIP, and PHI: effects on AC-, PLC-, and PLD-driven signaling systems in the primary glial cell cultures.
    Dejda A, Jozwiak-Bebenista M, Nowak JZ.
    Ann N Y Acad Sci; 2006 Jul 08; 1070():220-5. PubMed ID: 16888170
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. VPAC and PAC receptors: From ligands to function.
    Dickson L, Finlayson K.
    Pharmacol Ther; 2009 Mar 08; 121(3):294-316. PubMed ID: 19109992
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Neuroprotection: a comparative view of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide.
    Brenneman DE.
    Peptides; 2007 Sep 08; 28(9):1720-6. PubMed ID: 17513014
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.